Hims shares have roughly doubled since the start of the year, despite the FDA’s announcement last week that Novo Nordisk’s ...

Fintel reports that on February 18, 2025, Morgan Stanley downgraded their outlook for Hims & Hers Health (NYSE:HIMS) from ...

Shares of Hims & Hers Health (HIMS) are down at the time of writing after Morgan Stanley, led by four-star analyst Craig Hettenbach, ...

Healthcare stock Hims and Hers (HIMS) is sharply lower today but has contrarian potential next week ahead of earnings ...

Morgan Stanley downgraded Hims Hers Health Inc (NYSE:HIMS) to "Equal-weight" from "Overweight" as the stock’s recent strong performance leaves limited near-term upside, despite continued business ...

Hims & Hers Health Inc is a multi-specialty telehealth platform that connects consumers to licensed healthcare professionals, enabling them to access high-quality medical care for numerous conditions ...

Morgan Stanley downgraded telehealth firm Hims & Hers Health (NYSE:HIMS) to Equal Weight from Overweight on Tuesday ahead of its Q4 2024 results next week, citing the stock’s recent rally.

Morgan Stanley cut shares of Hims & Hers Health (NYSE:HIMS – Free Report) from an overweight rating to an equal weight rating ...

Hims & Hers Health Inc is a multi-specialty telehealth platform that connects consumers to licensed healthcare professionals, ...

周二，Morgan Stanley调整了对Hims & Hers Health, Inc. (NYSE: HIMS )的立场，将股票评级从增持下调至中性，同时将目标价从此前的42美元上调至60美元。该公司代表Craig ...

Morgan Stanley also drew scrutiny previously for fielding an all-white, all-male slate of candidates to succeed former CEO ...

Morgan Stanley analyst Craig Hettenbach downgraded Hims & Hers to Equal Weight from Overweight with a price target of $60, up from $42. The ...